AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

657.063

-2.060-0.31%

Number of Gainers:8

Number of Losers:15

Number of Flat:20

PE:- -

High:668.731

Open:663.741

Low:652.831

Close:659.123

Volume:33.88M

Turnover:180.84M

Market Cap:93.67B

Float Cap:90.54B

Loading ...

Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale

THOMSON REUTERS

Immutep - Targets Next Efti Clinical Trials Start in 2H Cy2027

THOMSON REUTERS

Thailand's Forex Reserves Rise to $283.1 Billion in August

MT Newswires Live

Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13%

MT Newswires Live

Immutep Targets 2H 2027 Start for Efti Trials in PD-L1-Negative Head and Neck Cancer, Soft Tissue Sarcoma

Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial

MT Newswires Live

CSL Seqirus Publishes Phase 3 Study Results for Influenza Vaccine

MT Newswires Live

Immutep Ltd-Immutep Outlines Focused Development Strategy for Efti

THOMSON REUTERS

Tissue Repair - Mark Bouw Replaces Dion Cohen as CFO Effective 10 September 2026

THOMSON REUTERS

Tissue Repair - Appoints Mark Bouw as Chief Financial Officer Effective Today

THOMSON REUTERS

Tissue Repair Ltd-Appointment of Chief Financial Officer

THOMSON REUTERS

AnteoTech CFO Scott Waddell Resigns

MT Newswires Live

Australia's CSL Slips on Trading Ex-Dividend, Among Benchmark's Top Percentage Losers

Anteotech Ltd-Resignation of Chief Financial Officer and Company Secretary

THOMSON REUTERS

Anteotech - Scott Waddell Resigns as CFO

THOMSON REUTERS

Inhibitor Therapeutics Announces Annual Shareholder Meeting

AnteoTech Strikes Battery Design, Prototyping Deal With Airspeeder; Shares Down 4%

MT Newswires Live

Australia's OncoSil Medical Gains Most in over 2 Months on Reaching 100-Th Patient Milestone

Prescient Therapeutics Extends Share Purchase Plan Closing Date

MT Newswires Live

Anteotech Discloses Next Generation Battery Agreement with Airspeeder

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":657.06305,"timestamp":1789538399653,"preClose":659.12286,"halted":0,"volume":33876933,"delay":0,"changeRate":-0.003125,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-2.059814,"latestTime":"09-16 16:00:00 AEST","open":663.74115,"high":668.7309,"low":652.8311,"amount":180844645,"amplitude":0.024123,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789516800000,1789538400000]],"turnoverRate":0.001328,"increases":8,"decrements":16,"flats":19,"marketCap":93671629289.75,"floatMarketCap":90538125826.625},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":668.7309,"amplitude":0.024123,"preClose":659.12286,"low":652.8311,"latestPrice":657.06305,"volume":33876933,"delay":0,"open":663.74115,"prevYearClose":644.3692,"prevWeekClose":634.95,"prevMonthClose":656.138,"prevQuarterClose":464.145,"fiveDayClose":655.041,"twentyDayClose":646.662,"sixtyDayClose":461.734,"secType":"PLATE","market":"AU","turnoverRate":0.001328,"marketCap":93671629289.75,"floatMarketCap":90538125826.625,"timestamp":1789538399653,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":8,"down":15,"flat":20},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666212615","title":"Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212615?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212325","title":"Immutep - Targets Next Efti Clinical Trials Start in 2H Cy2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212325?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666454239","title":"Thailand's Forex Reserves Rise to $283.1 Billion in August","url":"https://stock-news.laohu8.com/highlight/detail?id=2666454239","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666454239?lang=en_us&edition=fundamental","pubTime":"2026-09-11 16:01","pubTimestamp":1789113691,"startTime":"0","endTime":"0","summary":"Thailand's gross international reserves rose to $283.1 billion in August, according to data released by the Bank of Thailand  on Friday.The reading compares with the $275.4 billion recorded in the previous month.The monthly movement was primarily driven by a rise in foreign currency reserves, which reached $242.7 billion, while the central bank's gold holdings were valued at $33.6 billion. Meanwhile, the country's net forward position stood at $24.6 billion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7502","BOT.AU","BK7508","BOT","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666954810","title":"Paradigm Biopharmaceuticals Draws Down Final $2 Million of Tranche 4 From Convertible Note Facility; Shares Down 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666954810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666954810?lang=en_us&edition=fundamental","pubTime":"2026-09-11 11:50","pubTimestamp":1789098623,"startTime":"0","endTime":"0","summary":"Paradigm Biopharmaceuticals  drew down the remaining balance of tranche 4, valued at $2 million, under its $27 million convertible note facility with Obsidian Global Partners, according to a Friday Australian bourse filing.Following the drawdown, about $5 million remains available under the facility, providing continued financial flexibility to support phase 3 execution and broader commercial readiness activities, the filing added.The company's shares plunged 13% in recent Friday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","PAR.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666151081","title":"Immutep Targets 2H 2027 Start for Efti Trials in PD-L1-Negative Head and Neck Cancer, Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2666151081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666151081?lang=en_us&edition=fundamental","pubTime":"2026-09-11 10:32","pubTimestamp":1789093949,"startTime":"0","endTime":"0","summary":"Immutep targets 2H 2027 start for efti trials in PD-L1-negative head and neck cancer, soft tissue sarcomaImmutep reset efti’s registration strategy, prioritizing head and neck cancer in PDL1negative p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL8SLnt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512317","title":"Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512317?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:02","pubTimestamp":1789088547,"startTime":"0","endTime":"0","summary":"Immutep  conducted a root cause analysis covering clinical, pharmacological, and manufacturing aspects for its eftilagimod alfa drug candidate, or efti, which identified structural differences between the efti used in the discontinued TACTI-004 trial and the efti used in earlier successful clinical studies, according to a Friday Australian bourse filing.The differences, including a difference in N-glycan structure, are considered potentially relevant given the different immune activation profile observed in the TACTI-004 trial. Immutep believes that \"the unexpected outcome of TACTI-004\" cannot be explained by clinical factors or trial execution factors.Due to the analytical differences between efti manufactured at 200 L scale and efti manufactured at 2,000 L scale, a new manufacturing run of efti at 200 L scale was contracted.Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma in patients with negative PD-L1 expression","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMM.AU","BK4505","BK7508","BK4551","ROOT","BK4107","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666052514","title":"CSL Seqirus Publishes Phase 3 Study Results for Influenza Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2666052514","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666052514?lang=en_us&edition=fundamental","pubTime":"2026-09-11 08:52","pubTimestamp":1789087944,"startTime":"0","endTime":"0","summary":"CSL's  CSL Seqirus unit disclosed publication of pivotal phase 3 study results for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine  for influenza prevention in older adults in The Lancet Infectious Diseases, according to a Friday statement.The phase 3 randomized immunogenicity and safety study enrolled 7,699 adults aged 50 and older across eight countries and compared aQIVc with two enhanced influenza vaccines, demonstrating superiority versus the adjuvanted egg-based influenza vaccine comparator across all four influenza strains and age groups, and non-inferiority versus a recombinant influenza vaccine for three out of four strains in the 50-plus age group and four out of four strains in those aged 65 and older, the company said.The study also demonstrated immune responses that persisted throughout the influenza season and a well-tolerated safety profile, with most reactions mild or moderate and resolving within three days, CSL added.The study authors conclud","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7501","CSL.AU","BK7511","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519409","title":"Immutep Ltd-Immutep Outlines Focused Development Strategy for Efti","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519409?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081308,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUE9KKQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666872554","title":"Tissue Repair - Mark Bouw Replaces Dion Cohen as CFO Effective 10 September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2666872554","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666872554?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:53","pubTimestamp":1789008817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUEBQJ73Y:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRP.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666825554","title":"Tissue Repair - Appoints Mark Bouw as Chief Financial Officer Effective Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2666825554","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666825554?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:53","pubTimestamp":1789008817,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUEBQJ73Y:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRP.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666554829","title":"Tissue Repair Ltd-Appointment of Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2666554829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666554829?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:53","pubTimestamp":1789008817,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUEBQJ73Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","TRP.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666305163","title":"AnteoTech CFO Scott Waddell Resigns","url":"https://stock-news.laohu8.com/highlight/detail?id=2666305163","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666305163?lang=en_us&edition=fundamental","pubTime":"2026-09-09 08:53","pubTimestamp":1788915201,"startTime":"0","endTime":"0","summary":"AnteoTech (ASX:ADO) said CFO Scott Waddell has resigned to pursue other business interests, according to a Wednesday filing with the Australian bourse.The company will launch a search for Waddell's successor.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7036","ADO.AU","BK7508","BK7048","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666031153","title":"Australia's CSL Slips on Trading Ex-Dividend, Among Benchmark's Top Percentage Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666031153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666031153?lang=en_us&edition=fundamental","pubTime":"2026-09-09 08:15","pubTimestamp":1788912921,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's CSL slips on trading ex-dividend, among benchmark's top percentage losers** Shares of CSLCSL.AXfall as much as2.7% to A$170.01, their lowest level since Aug 24** Shares of pharmaceutical giant post biggest intraday pct drop since Aug 21** Shares trade ex-dividend;declaredfinal dividend of $1.62 per share in August** Co among top percentage losers in Australia's S&P/ASX 200 index.AXJO, which is up 0.2%** YTD, shares down 0.6%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nL4N45100G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","BK7501","BK7508","CSL.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308418","title":"Anteotech Ltd-Resignation of Chief Financial Officer and Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308418","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308418?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:12","pubTimestamp":1788909139,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUE39RXHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7048","BK7036","BK7508","ADO.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308413","title":"Anteotech - Scott Waddell Resigns as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308413","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308413?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:12","pubTimestamp":1788909139,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUE39RXHG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7048","ADO.AU","BK7501","BK7036","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666952370","title":"Inhibitor Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666952370","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666952370?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:16","pubTimestamp":1788902169,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics announces annual shareholder meetingInhibitor Therapeutics will hold its annual stockholders’ meeting virtually on Sept. 15, 2026.Stockholders will vote on matters set out in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL7Sc3qt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","IE00B64PRP62.GBP","BK7096","BK4588","LU2095319765.USD","BK7508","SG9999014005.SGD","INTI","BK4585","LU0314104364.USD","IE00BQXX3D17.EUR","LU2210149790.SGD","BK4112","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BQXX3C00.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","MYX.AU","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK4139","IE00BKPKM429.USD","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349770","title":"AnteoTech Strikes Battery Design, Prototyping Deal With Airspeeder; Shares Down 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349770","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665349770?lang=en_us&edition=fundamental","pubTime":"2026-09-08 11:03","pubTimestamp":1788836612,"startTime":"0","endTime":"0","summary":"AnteoTech  struck a supply deal for next-generation battery design and prototyping with Adelaide-based electric flying car business Airspeeder, according to a Tuesday filing with the Australian bourse.Airspeeder, the world's first racing series for manned electric-powered flying cars, is establishing teams in several countries including Australia and the US. AnteoTech said it will be the foundational battery development consortium lead for the Australian team.AnteoTech's lithium-ion battery technology will help improve the flight time and power performance of new electric vertical take-off and landing aircraft models, per the filing.The company's shares fell 4% in recent Tuesday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLF.AU","VAS.AU","XKO.AU","OZR.AU","EIGA.AU","IIGF.AU","ZYAU.AU","BK7508","BEAR.AU","BK7036","IOZ.AU","XAO.AU","DACE.AU","ADO.AU","XJO.AU","E200.AU","OZF.AU","STW.AU","VAP.AU","BK7048","BBOZ.AU","QFN.AU","GEAR.AU","GIVE.AU","IISV.AU","IMLC.AU","QRE.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665349558","title":"Australia's OncoSil Medical Gains Most in over 2 Months on Reaching 100-Th Patient Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2665349558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665349558?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:29","pubTimestamp":1788834581,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's OncoSil Medical gains most in over 2 months on reaching 100-th patient milestone** Shares of Australia's OncoSil MedicalOSL.AXrise as much as 19.2% at A$1.120, on track for their bigg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4N45005J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OSL.AU","BK7048","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665467673","title":"Prescient Therapeutics Extends Share Purchase Plan Closing Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2665467673","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665467673?lang=en_us&edition=fundamental","pubTime":"2026-09-08 10:06","pubTimestamp":1788833182,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  has extended the closing date of its share purchase plan  to Sept. 15 from Sept. 8, giving eligible shareholders more time to participate in the AU$7 million capital raising following delays in receiving documentation, according to a Tuesday filing with the Australian bourse.Eligible shareholders can apply under the SPP for up to AU$30,000 worth of new shares at AU$0.065 each, per the filing.The funds will be used to support the advancement of PTX-100 beyond the Dose Optimization Committee meeting, expected in December, and to guide the study's continuation and further development, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","PTX.AU","BK7508","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665466983","title":"Anteotech Discloses Next Generation Battery Agreement with Airspeeder","url":"https://stock-news.laohu8.com/highlight/detail?id=2665466983","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665466983?lang=en_us&edition=fundamental","pubTime":"2026-09-08 09:41","pubTimestamp":1788831719,"startTime":"0","endTime":"0","summary":"BRIEF-Anteotech Discloses Next Generation Battery Agreement With AirspeederSept 8 (Reuters)-Anteotech LtdADO.AX:ANTEOTECH LTD-NEXT GENERATION BATTERY AGREEMENT WITH AIRSPEEDERANTEOTECH - SIGNS SUPPLY ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nTUE68J3DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7036","ADO.AU","BK7048","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":71,"code":"91000000","status":"200"}]}}